Venetoclax Extension Study for Leukemia

Recruiting in Palo Alto (17 mi)

+94 other locations

Age: Any Age

Sex: Any

Travel: May Be Covered

Time Reimbursement: Varies

Trial Phase: Phase 3

Waitlist Available

Sponsor: AbbVie

No Placebo Group

Pivotal Trial (Near Approval)

Prior Safety Data

Breakthrough Therapy

Approved in 2 Jurisdictions

Trial Summary

What is the purpose of this trial?

The purpose of this extension study is to provide venetoclax and obtain long-term safety data for subjects who continue to tolerate and derive benefit from receiving venetoclax in ongoing studies.

Research Team

ABBVIE INC.

Principal Investigator

AbbVie

Eligibility Criteria

This trial is for people who have been part of a venetoclax study, are still benefiting from it without major issues, and aren't pregnant or breastfeeding. Men must agree not to donate sperm during the trial.

Inclusion Criteria

I am currently taking venetoclax for my condition and it's working without severe side effects.

I am not pregnant or breastfeeding.

I agree not to donate sperm.

Exclusion Criteria

Not applicable.

Treatment Details

Interventions

Venetoclax (B-cell lymphoma-2 (BCL-2) inhibitor)

Trial OverviewThe study continues giving venetoclax to participants from previous trials to gather more information on its long-term safety and ongoing effectiveness in treating various types of blood cancers.

Participant Groups

1Treatment groups

Experimental Treatment

Group I: VenetoclaxExperimental Treatment1 Intervention

Venetoclax at the same dose administered to each subject during the previous study in which they were enrolled.